drugset
drugset / Trial / NCT01225172

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

NCT01225172 ↗

Phase 2 Terminated 77 enrolled Bristol-Myers Squibb Mayo Clinic · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

Timeline

Start
2010-12-31
Primary completion
2014-11-30
Completion
2014-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-754807 Small molecule 100 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral

Indications

breast cancer